• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4623524)   Today's Articles (362)   Subscriber (49411)
For: Kitamura A, Hoshino K, Kimura Y, Hayakawa I, Sato K. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995;39:1467-71. [PMID: 7492087 PMCID: PMC162764 DOI: 10.1128/aac.39.7.1467] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]  Open
Number Cited by Other Article(s)
1
Faleye OS, Boya BR, Lee JH, Choi I, Lee J. Halogenated Antimicrobial Agents to Combat Drug-Resistant Pathogens. Pharmacol Rev 2023;76:90-141. [PMID: 37845080 DOI: 10.1124/pharmrev.123.000863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Revised: 08/07/2023] [Accepted: 09/29/2023] [Indexed: 10/18/2023]  Open
2
Huang YS, Wang JT, Sheng WH, Chuang YC, Chang SC. Comparative in vitro activity of sitafloxacin against bacteremic isolates of carbapenem resistant Acinetobacter baumannii complex. JOURNAL OF MICROBIOLOGY, IMMUNOLOGY, AND INFECTION = WEI MIAN YU GAN RAN ZA ZHI 2014;48:545-51. [PMID: 24662017 DOI: 10.1016/j.jmii.2014.02.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/28/2013] [Revised: 01/23/2014] [Accepted: 02/06/2014] [Indexed: 11/15/2022]
3
Fu Y, Zhang W, Wang H, Zhao S, Chen Y, Meng F, Zhang Y, Xu H, Chen X, Zhang F. Specific patterns of gyrA mutations determine the resistance difference to ciprofloxacin and levofloxacin in Klebsiella pneumoniae and Escherichia coli. BMC Infect Dis 2013;13:8. [PMID: 23295059 PMCID: PMC3576228 DOI: 10.1186/1471-2334-13-8] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2012] [Accepted: 01/02/2013] [Indexed: 02/04/2023]  Open
4
Minovski N, Perdih A, Novic M, Solmajer T. Cluster-based molecular docking study forin silicoidentification of novel 6-fluoroquinolones as potential inhibitors againstMycobacterium tuberculosis. J Comput Chem 2012;34:790-801. [DOI: 10.1002/jcc.23205] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2012] [Revised: 10/22/2012] [Accepted: 11/30/2012] [Indexed: 01/15/2023]
5
Ghebremedhin B. Bacterial Infections in the Elderly Patient: Focus on Sitafloxacin. ACTA ACUST UNITED AC 2012. [DOI: 10.4137/cmt.s7435] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
6
Combinatorially-generated library of 6-fluoroquinolone analogs as potential novel antitubercular agents: a chemometric and molecular modeling assessment. J Mol Model 2011;18:1735-53. [DOI: 10.1007/s00894-011-1179-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2011] [Accepted: 07/04/2011] [Indexed: 01/15/2023]
7
Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. Antimicrob Agents Chemother 2011;55:4261-6. [PMID: 21730117 DOI: 10.1128/aac.01105-10] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]  Open
8
van Westreenen M, Tiddens HAWM. New antimicrobial strategies in cystic fibrosis. Paediatr Drugs 2010;12:343-52. [PMID: 21028914 DOI: 10.2165/11316240-000000000-00000] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
9
El Solh AA, Alhajhusain A. Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother 2009;64:229-238. [DOI: 10.1093/jac/dkp201] [Citation(s) in RCA: 108] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]  Open
10
Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates. Antimicrob Agents Chemother 2008;53:229-34. [PMID: 18838594 DOI: 10.1128/aac.00722-08] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
11
Ward KW, Lepage JF, Driot JY. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocul Pharmacol Ther 2007;23:243-56. [PMID: 17593008 DOI: 10.1089/jop.2006.0137] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
12
Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007;13:560-78. [PMID: 17266725 DOI: 10.1111/j.1469-0691.2007.01681.x] [Citation(s) in RCA: 367] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
13
Epstein SP, Bottone EJ, Asbell PA. Susceptibility Testing of Clinical Isolates of Pseudomonas aeruginosa to Levofloxacin, Moxifloxacin, and Gatifloxacin as a Guide to Treating Pseudomonas Ocular Infections. Eye Contact Lens 2006;32:240-4. [PMID: 16974157 DOI: 10.1097/01.icl.0000215432.96891.1f] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
14
Cheng AFB, Yew WW, Chan EWC, Chin ML, Hui MMM, Chan RCY. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004;48:596-601. [PMID: 14742214 PMCID: PMC321542 DOI: 10.1128/aac.48.2.596-601.2004] [Citation(s) in RCA: 100] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
15
Allen GP, Kaatz GW, Rybak MJ. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003;47:2606-14. [PMID: 12878526 PMCID: PMC166082 DOI: 10.1128/aac.47.8.2606-2614.2003] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
16
Nakajima A, Sugimoto Y, Yoneyama H, Nakae T. High-level fluoroquinolone resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM efflux pump and the DNA gyrase mutation. Microbiol Immunol 2003;46:391-5. [PMID: 12153116 DOI: 10.1111/j.1348-0421.2002.tb02711.x] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
17
Takei M, Fukuda H, Kishii R, Kadowaki Y, Atobe Y, Hosaka M. Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus. Antimicrob Agents Chemother 2002;46:3337-8. [PMID: 12234876 PMCID: PMC128794 DOI: 10.1128/aac.46.10.3337-3338.2002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
18
Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob Agents Chemother 2002;46:522-4. [PMID: 11796368 PMCID: PMC127057 DOI: 10.1128/aac.46.2.522-524.2002] [Citation(s) in RCA: 82] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
19
Lu T, Zhao X, Li X, Drlica-Wagner A, Wang JY, Domagala J, Drlica K. Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob Agents Chemother 2001;45:2703-9. [PMID: 11557458 PMCID: PMC90720 DOI: 10.1128/aac.45.10.2703-2709.2001] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
20
Schmitz FJ, Boos M, Mayer S, Hafner D, Jagusch H, Verhoef J, Fluit AC. Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:2666-7. [PMID: 11523528 PMCID: PMC90713 DOI: 10.1128/aac.45.9.2666-2667.2001] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
21
Friedman SM, Lu T, Drlica K. Mutation in the DNA gyrase A Gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob Agents Chemother 2001;45:2378-80. [PMID: 11451702 PMCID: PMC90659 DOI: 10.1128/aac.45.8.2378-2380.2001] [Citation(s) in RCA: 83] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
22
Akasaka T, Tanaka M, Yamaguchi A, Sato K. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother 2001;45:2263-8. [PMID: 11451683 PMCID: PMC90640 DOI: 10.1128/aac.45.8.2263-2268.2001] [Citation(s) in RCA: 125] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
23
Setti EL, Micetich RG. New trends in antimicrobial development. EXS 2001;89:29-53. [PMID: 10997281 DOI: 10.1007/978-3-0348-8393-1_3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
24
Fish DN, North DS. Gatifloxacin, an advanced 8-methoxy fluoroquinolone. Pharmacotherapy 2001;21:35-59. [PMID: 11191737 DOI: 10.1592/phco.21.1.35.34440] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
25
Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 2000;16:5-15. [PMID: 11185413 DOI: 10.1016/s0924-8579(00)00192-8] [Citation(s) in RCA: 387] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
26
Kaneko A, Sasaki J, Shimadzu M, Kanayama A, Saika T, Kobayashi I. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci. J Antimicrob Chemother 2000;45:771-5. [PMID: 10837428 DOI: 10.1093/jac/45.6.771] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
27
Andriole VT. The future of the quinolones. Drugs 1999;58 Suppl 2:1-5. [PMID: 10553697 DOI: 10.2165/00003495-199958002-00001] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
28
Lu T, Zhao X, Drlica K. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob Agents Chemother 1999;43:2969-74. [PMID: 10582891 PMCID: PMC89596 DOI: 10.1128/aac.43.12.2969] [Citation(s) in RCA: 72] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
29
Chu DT. Recent progress in novel macrolides, quinolones, and 2-pyridones to overcome bacterial resistance. Med Res Rev 1999;19:497-520. [PMID: 10557367 DOI: 10.1002/(sici)1098-1128(199911)19:6<497::aid-med3>3.0.co;2-r] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
30
Zhao BY, Pine R, Domagala J, Drlica K. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. Antimicrob Agents Chemother 1999;43:661-6. [PMID: 10049284 PMCID: PMC89177 DOI: 10.1128/aac.43.3.661] [Citation(s) in RCA: 77] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
31
Akasaka T, Onodera Y, Tanaka M, Sato K. Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV. Antimicrob Agents Chemother 1999;43:530-6. [PMID: 10049263 PMCID: PMC89156 DOI: 10.1128/aac.43.3.530] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
32
Blondeau JM. Expanded activity and utility of the new fluoroquinolones: a review. Clin Ther 1999;21:3-40; discussion 1-2. [PMID: 10090423 DOI: 10.1016/s0149-2918(00)88266-1] [Citation(s) in RCA: 165] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
33
Dong Y, Xu C, Zhao X, Domagala J, Drlica K. Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob Agents Chemother 1998;42:2978-84. [PMID: 9797236 PMCID: PMC105976 DOI: 10.1128/aac.42.11.2978] [Citation(s) in RCA: 79] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
34
Lee S, Park T, Lee Y. Structure-activity relationship of fluoroquinolone in Escherichia coli. Arch Pharm Res 1998;21:106-12. [PMID: 9875416 DOI: 10.1007/bf02974013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
35
Zhao X, Wang JY, Xu C, Dong Y, Zhou J, Domagala J, Drlica K. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob Agents Chemother 1998;42:956-8. [PMID: 9559820 PMCID: PMC105579 DOI: 10.1128/aac.42.4.956] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]  Open
36
Antimicrobial Activity of a New Fluoroquinolone, DU-6859a, against Quinolone-Resistant Clinical Isolates of Pseudomonas aeruginosa with Genetic Alterations in the GyrA Subunit of DNA Gyrase and the ParC Subunit of Topoisomerase IV. J Infect Chemother 1998. [DOI: 10.1007/bf02491517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
37
Zhao X, Xu C, Domagala J, Drlica K. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci U S A 1997;94:13991-6. [PMID: 9391140 PMCID: PMC28420 DOI: 10.1073/pnas.94.25.13991] [Citation(s) in RCA: 159] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]  Open
38
Deguchi T, Yasuda M, Nakano M, Ozeki S, Kanematsu E, Nishino Y, Kawada Y. Improved antimicrobial activity of DU-6859a, a new fluoroquinolone, against quinolone-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates with alterations in GyrA and ParC proteins. Antimicrob Agents Chemother 1997;41:2544-6. [PMID: 9371364 PMCID: PMC164159 DOI: 10.1128/aac.41.11.2544] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]  Open
39
Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997;61:377-92. [PMID: 9293187 PMCID: PMC232616 DOI: 10.1128/mmbr.61.3.377-392.1997] [Citation(s) in RCA: 425] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]  Open
40
Vrany JD, Stewart PS, Suci PA. Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited by Pseudomonas aeruginosa bofilms displaying rapid-transport characteristics. Antimicrob Agents Chemother 1997;41:1352-8. [PMID: 9174198 PMCID: PMC163914 DOI: 10.1128/aac.41.6.1352] [Citation(s) in RCA: 77] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]  Open
41
Chu DT, Plattner JJ, Katz L. New directions in antibacterial research. J Med Chem 1996;39:3853-74. [PMID: 8831751 DOI: 10.1021/jm960294s] [Citation(s) in RCA: 231] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
42
Kumagai Y, Kato JI, Hoshino K, Akasaka T, Sato K, Ikeda H. Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother 1996;40:710-14. [PMID: 8851598 PMCID: PMC163185 DOI: 10.1128/aac.40.3.710] [Citation(s) in RCA: 68] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]  Open
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA